HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) and increased the price target from $3.75 to $5. This adjustment suggests a positive outlook on the company's future performance.
November 17, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akebia Therapeutics' stock may see a positive short term impact due to the maintained Buy rating and raised price target from $3.75 to $5 by HC Wainwright & Co.
Analyst ratings and price target adjustments are significant indicators for investors. The increase in price target by HC Wainwright & Co. reflects a bullish stance on Akebia Therapeutics, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100